How APAC CROs Are Putting AI to Work
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
Chong Kun Dang Pharmaceutical became the first Korean pharmaceutical company to export products to the US market through the obtainment of the U.S. FDA approval.
Chong Kun Dang Pharmaceutical Corp is one of the leading Korean pharmaceutical manufacturers and has a great strength on domestic sales not only with prescription drugs indicated for anti-hypertension, anti-hyperlipidemia and anti-diabetics but also with OTC drugs such a Penzal, Prefemine, Modcol and consumer health such as insecticides, hairdye, etc.
Their high-tech manufacturing facility, Cheon-An plant located in Cheon-An City, Chung Cheong Nam Do has an area of 13,700㎡ and gross floor area of 5,000㎡ .
Here the process of dispensing raw materials, production, packaging and release of finished products is controlled by an automated warehousing system.
Chong Kun Dang was the first in Korea to run its own research institute; it also invested a huge
portion of its resources in nurturing and training research manpower.
Chong Kun Dang Research Institute is characterized by three independent laboratories:
The New Drug Discovery Labs, for identifying innovative drug candidates, The Technology Development Labs, dedicated to generic drugs, APIs, and botanical drugs,
and The Bio Research Labs for developing antibodies, vaccines, and recombinant proteins.
Chong Kun Dang has distinguished achievements in drug development including the following :
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two…
We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum…
Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity…
Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical…
I believe we can position Korea as a true global leader in biohealth innovation Lee Hyung Hoon, Vice Minister at Korea’s Ministry of Health and Welfare, outlines his vision for…
We are actively evolving into a nation that discovers innovative drug candidates Korea’s clinical trial sector has spent the past two decades transforming itself from a fast follower into one…
Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the…
What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary…
Donghoon Lee outlines SK Biopharmaceuticals’ transformation into a global neuroscience player. He discusses the growth of its epilepsy profile, selective expansion into Parkinson’s disease and oncology, and acquisitions. Lee also…
See our Cookie Privacy Policy Here
